Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition.

J Dermatolog TreatMay 6, 2026 (epub)
Case ReportDermatologyRheumatology

Mandisi Brendon Nkala, Firouzeh Niakosari

✦ AI-curated · Sources linked

Case in brief

A 55-year-old woman with seropositive rheumatoid arthritis developed progressive alopecia areata while being treated with golimumab and leflunomide. Despite receiving intralesional corticosteroids over 14 months, her condition worsened. Following the initiation of JAK1 inhibition with upadacitinib, she experienced significant hair regrowth within six weeks, with her Severity of Alopecia Tool (SALT) score improving from approximately 50 to 15 by three months.

Diagnostic / clinical pearl

Clinicians should consider the potential for alopecia areata to develop during TNF-α inhibitor therapy and the possible benefit of JAK1 inhibition in such cases.

Source

PubMed · PMID 42089250

Published in J Dermatolog Treat. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.